A more recent study performed on stage 1–5 CKD patients showed no evidence of a decreasing effect of 25D on PTH lowering until 25D levels of 42–48 ng/mL [22], suggesting a higher VD target in CKD without any additional risk of hypercalcemia and hyperphosphatemia. This evidence concerns the gene PTH and chronic kidney disease.